Advances in immunotherapy for pleural malignant mesothelioma

曾然,刘芳,杨锦,项轶
DOI: https://doi.org/10.3760/cma.j.cn101548-20210524-00059
2022-01-01
Abstract:Malignant pleural mesothelioma (MPM) is malignant cancer associated with asbestos exposure. MPM is characterized by a long incubation period, difficult diagnosis at the early phase and poor prognosis. Several kinds of therapy remain ineffective, including chemotherapy, radiotherapy, and anti-angiogenesis therapy. Recently, immunotherapy has become a promoting strategy in many cancer types, and many clinical trials show the anti-tumor efficacy of immune checkpoint inhibitors (ICIs) in advanced MPM. Among these ICIs, nivolumab (PD-1inhibitors) plus ipilimumab (CTLA-4 inhibitors) was approved as first-line treatment for advanced MPM patients, which marks a significant milestone for the treatment of this disease. In this review, we summarize the advances in immunotherapy for MPM, mainly focusing on the appliances of ICIs, mesothelin-targeted therapy, and the advances of predictive biomarkers.
What problem does this paper attempt to address?